Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Seragen

Executive Summary

Firms reach final agreement Aug. 3 for Lilly to license Seragen's IL-2 fusion toxin for use in cancer therapies. Lilly agrees to fund all further development at an estimated cost of $17 mil. Payments to Seragen under the agreement, first announced in July ("The Pink Sheet" July 18, T&G-5), will total an additional $45 mil. Seragen also will pursue development of the fusion toxin for psoriasis
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel